Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis
{{output}}
Objective: Aim: The primary endpoint was the incidence of major HRAEs. Secondary endpoints included LVAD thrombosis, stroke, major bleeding, non-central nervous system thromboembolism, and all-cause mortality. ... ...
